Results from the GIADA trial also suggest that ER+/HER2− breast cancers with an immune-activated state and downregulation of hormone receptor pathways respond favourably to sequential chemotherapy and anti–PD–1 therapy [49]. Here, ESR1 is linked to breast carcinoma.